Related Experiment Video
Updated: Apr 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Natalizumab to fingolimod: Questions answered, unanswered, and unasked
Olaf Stüve1, Dennis Bourdette2
1From the Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas; the Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas; the Department of Neurology (O.S.), Klinikum rechts der Isar, Technische Universität München, Germany; the Department of Neurology (D.B.), Oregon Health & Science University, Portland; and the Multiple Sclerosis Center of Excellence-West (D.B.), VA Portland Health Care Center, OR. olaf.stuve@utsouthwestern.edu.
No abstract available in PubMed .
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents